Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2022 | Exciting updates in essential thrombocythemia: exploring novel agents

Harinder Gill • 10 Dec 2022
ASH 2022
Essential Thrombocythemia Myeloproliferative Neoplasms Rare Diseases Bomedemstat Imetelstat Ropeginterferon alfa-2b

Harinder Gill, MBBS, PDipID, MD, MRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China, discusses exciting updates in the field of essential thrombocythemia (ET), highlighting novel agents being explored, including ropeginterferon alfa-2b, imetelstat, and bomedemstat. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Harinder Gill

JAK inhibition in MF: monotherapy versus combination treatment 2:20
JAK inhibition in MF: monotherapy versus combination treatment
Harinder Gill • 11 Dec 2023
Bomedemstat combined with ruxolitinib for the treatment of MF: early results of a Phase II trial 2:41
Bomedemstat combined with ruxolitinib for the treatment of MF: early results of a Phase II trial
Harinder Gill • 11 Dec 2023
Updated results of the AAA regimen in newly-diagnosed acute promyelocytic leukemia 2:05
Updated results of the AAA regimen in newly-diagnosed acute promyelocytic leukemia
Harinder Gill • 11 Dec 2023
Phase II study of all-oral AAA regimen for patients with newly diagnosed APL 3:10
Phase II study of all-oral AAA regimen for patients with newly diagnosed APL
Harinder Gill • 10 Jun 2023

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals